Join ReadMyMRI’s Vision for the Future

A Unique Opportunity to Own a Stake in a Growing Healthcare Innovation

A Secondary Equity Sale for Early Investors

AI—powered healthcare solutions are transforming medical imaging, and ReadMyMRI.com is leading the way. With an AI-driven reporting platform designed for both patients and healthcare providers, we are creating a smarter, faster, and more accessible way to interpret the results of MRI, CT, PET, and ultrasound scans.

For a limited time, accredited investors can purchase equity directly from the majority owner, securing a stake in one of the fastest-growing AI healthcare markets before institutional investors enter.

Market Opportunity: A $14B+ AI Healthcare Revolution

  • AI in medical imaging is projected to grow from $1.28 billion in 2024 to $14.46 billion by 2034, expanding at a 27.1% CAGR.

  • Companies like Rad AI ($525M valuation) and Neko Health ($1.7B valuation) prove that AI-driven healthcare solutions are rapidly increasing in value.

  • Medical imaging is projected to continue to grow, creating huge demand for scalable, automated report solutions like ReadMyMRI.

Why This Investment Opportunity is Unique

Unlike traditional funding rounds, this is a secondary equity sale, meaning:

✅ Investors acquire equity directly from the majority owner—not through newly issued shares.
✅ No dilution of company ownership—you gain a stake without affecting company financials.
✅ A chance to own shares ahead of major valuation growth as ReadMyMRI continues expanding in B2B and direct-to-consumer markets.

This exclusive opportunity is limited, with shares available on a first-come, first-served basis.

Why Invest in ReadMyMRI?

✅ Multi-Billion Dollar Market Potential – AI-powered imaging is a $14B+ industry, growing at 27% annually.
✅ Scalable Business Model – Dual revenue streams from direct-to-consumer (DTC) sales and high-value B2B partnerships.
✅ Established Demand – Everyone is confused by their reports; we make the results understandable and provide questions to ask your doctor.
✅ Limited Availability – This secondary sale is only open to select investors before institutional rounds.

Next Steps: Secure Your Stake in ReadMyMRI

This exclusive secondary equity sale is available for a limited time. Accredited investors can own shares in ReadMyMRI before the company expands.

Join us in shaping the future of AI-powered medical reporting—before the next phase of exponential growth.

Projected Growth of Medical Imaging and AI Healthcare Markets (2025-2034)

Annual Medical Imaging Scans & Projected Growth (2025-2034)

Imaging Type Current Annual Scans (millions) CAGR (10 Years) Projected Scans (2034)
MRI 40M 5% 65M
CT 80M 4% 119M
Ultrasound 300M 3% 403M
X-Ray 600M 2% 731M

The information on this website is for informational purposes only. It does not constitute an offer, solicitation, or recommendation to buy securities or invest in ReadMyMRI, Inc. Any financial projections or forecasts are speculative. They should not be considered guarantees of future performance. Investing in early-stage companies involves significant risks, and prospective investors should seek independent legal and financial advice before making any investment decisions.

Logo with text 'ReadMyMRI'

 FAQs

  • A secondary equity sale means investors are purchasing shares directly from the majority owner, rather than investing new capital into the company. This allows investors to acquire ownership in ReadMyMRI without dilution of existing shares or changes to the company’s financials.

  • In a traditional funding round, new shares are issued, and the funds raised go into company growth initiatives. In this secondary sale, investors are acquiring existing equity—meaning their investment goes to the selling shareholder instead of directly funding operations.

  • This sale provides select investors with an exclusive opportunity to secure early-stage equity before a potential institutional funding round or exit event. The company remains well-positioned for continued growth in both the direct-to-consumer (DTC) and B2B healthcare provider markets.

  • Based on comparable AI medical imaging companies and industry benchmarks, ReadMyMRI’s pre-market valuation is estimated between $50M and $150M. Companies in similar sectors, such as Rad AI ($525M valuation) and Neko Health ($1.7B valuation), have demonstrated significant growth in the AI-driven healthcare space.

  • The AI medical imaging market is projected to grow from $1.28 billion in 2024 to $14.46 billion by 2034, expanding at a 27.1% CAGR. Increased adoption by radiologists, hospitals, and telemedicine providers makes AI-powered reporting one of the fastest-growing sectors in healthcare.

  • Interested investors will go through the following steps:
    1️⃣ Request Investor Materials – Receive a full breakdown of financials, valuation, and investment terms.
    2️⃣ Due Diligence & Agreement Review – Review the share purchase agreement (SPA) and confirm details.
    3️⃣ Finalize Investment & Transfer Ownership – Upon closing, shares are legally transferred to the investor.

  • Yes, the minimum investment amount is $25,000, ensuring alignment with accredited investors and strategic partners.

  • This depends on the investment structure and number of shares acquired. Investors will receive details on shareholder rights, governance, and any voting privileges during the due diligence phase.

  • While all investments carry risks, ReadMyMRI is positioned for significant growth as AI adoption in medical imaging accelerates. Potential exit strategies include:
    ✅ Acquisition by a larger healthcare AI company or imaging platform
    ✅ Institutional funding rounds at higher valuations
    ✅ Potential IPO or secondary public market sale

  • As with any investment, there are inherent risks, including:
    ⚠ Market Competition – AI in radiology is competitive, though ReadMyMRI’s unique DTC & B2B hybrid model offers differentiation.
    ⚠ Regulatory Considerations – Compliance with healthcare and AI regulations is a key focus for long-term scalability.
    ⚠ Adoption Rate – While AI-powered diagnostics are rapidly expanding, adoption timelines can vary across different healthcare systems.

  • At this time, the secondary sale is only open to accredited investors who meet SEC-defined income/net worth requirements.